For the third time this yr, a affected person handled with a Sarepta Therapeutics gene remedy has died, a revelation that comes as the corporate tries to earn again affected person and investor belief amid a sequence of security setbacks.
The primary two fatalities had been teenage boys handled with the commercialized Duchenne muscular dystrophy gene remedy Elevidys. The most recent fatality was a 51-year-old man who acquired SRP-9004, an experimental gene remedy for limb-girdle muscular dystrophy 2D/R3. All three sufferers died after growing acute liver failure.
BioCentury first reported the most recent fatality late Thursday. Sarepta confirmed the event, then held a convention name on Friday, throughout which monetary analysts peppered executives with questions on why they didn’t disclose the fatality Wednesday, when the corporate introduced a cash-saving company restructuring that may lower 36% of its employees and cease additional improvement of two limb girdle applications, together with SRP-9004.
Sarepta CEO Doug Ingram defended the corporate’s stage of disclosure, telling analysts that the fatality was not a cloth occasion nor was it central to the matters mentioned Wednesday. He added that the corporate’s choice to not proceed with the 2 limb-girdle applications was monetary, and was made impartial of the fatality. Ingram defined that there was no additional dosing within the limb-girdle research, so the correct option to focus on the fatality can be within the presentation of the complete research outcomes, which Sarepta plans to do at a future medical assembly.
“As pertains to materiality, definitely if there was a cloth change within the security sign of certainly one of our marketed therapies, we might disclose that publicly,” Ingram stated. “I feel we now have, I imagine, a really laudable historical past of being terribly clear, not solely with the doctor and affected person neighborhood, however with our investor base as effectively.”
Louise Rodino-Klapac, the corporate’s head of R&D and chief scientific officer, stated the deceased limb-girdle affected person was a 51-year-old, non-ambulatory man. The demise occurred a month in the past, about 11 weeks after dosing. Rodino-Klapac stated Sarepta notified the FDA first in regards to the life-threatening liver complication, then in regards to the demise.
“The FDA was correctly knowledgeable alongside the way in which of this case,” she stated.
One other analyst requested whether or not Sarepta is conscious of another fatalities related to its gene therapies. Rodino-Klapac replied no.
Regardless of Ingram’s clarification, analysts and buyers see the developments with SRP-9004 as materials and related to the corporate and to Elevidys. Sarepta’s gene therapies are delivered to their locations within the physique aboard adeno-associated viruses (AAV). Hostile reactions are a recognized danger of genetic medicines that use these engineered viruses. In a analysis notice, Leerink Companions analyst Joseph Schwartz famous that the AAV vector used for SRP-9004 is identical one utilized in Elevidys. It’s additionally utilized in SRP-9003, a Sarepta gene remedy candidate for an additional type of limb-girdle muscular dystrophy. Sarepta plans to file an software later this yr in search of FDA approval of SRP-9003.
William Blair analyst Sami Corwin stated in a analysis notice that given the deceased limb-girdle affected person’s age, the excessive dose of the AAV-based gene remedy was the doubtless reason behind the liver failure. She stated this fatality might result in better scrutiny of SRP-9003. It might additionally amplify hesitancy of Duchenne sufferers to make use of Elevidys and improve investor mistrust because of the failure to reveal the demise, she stated.
In one other analysis notice, Corwin stated William Blair believes the shortage of transparency from Sarepta administration is contributing to the corporate’s inventory value decline. Shares closed Friday at $14.07, down practically 36% from Thursday’s shut. Corwin added that the shortage of transparency is dangerous to the AAV gene remedy subject extra broadly.
Elevidys initially seemed to be a vibrant spot in Sarepta’s company shakeup announcement. The corporate stated Wednesday that the FDA requested for a label replace to incorporate a black field warning, which analysts interpreted as optimistic as a result of it suggests the product received’t be pulled from the market. However Elevidys may not be obtainable to Duchenne sufferers for much longer. The FDA will ask Sarepta to cease all shipments of the gene remedy, Reuters reported Friday afternoon, citing an unnamed supply conversant in the matter. The FDA has been investigating the fatalities related to Elevidys, an inquiry it introduced in late June following the report of the second demise.
In a notice despatched to buyers after Friday’s market shut, Leerink’s Schwartz stated his agency just isn’t assured that Sarepta understands the liver security sign sufficient to establish a affected person inhabitants the place the protection danger is suitable. He added the FDA could wish to make an instance of Elevidys and elimination of the product from the market is changing into a respectable danger. Leerink can not advocate Sarepta’s inventory “below any circumstances.”
“We strongly disagree with administration concerning their opinion on the materiality of the third demise for his or her gene remedy platform, and once more we predict this considerably undermines their credibility,” Schwartz stated. “We additionally disagree with administration’s opinion that this demise doesn’t have readthrough to Elevidys and see mounting business danger for that program following one other gene remedy demise.”
(Story up to date all through with further analyst feedback.)
Photograph: Michael Nagle/Bloomberg, through Getty Pictures
